Summit Therapeutics Inc. (SMMT) — 8-K Filings

8-K Filings (29)

• Summit Therapeutics Files 8-K — Nov 7, 2025 Risk: low
  Summit Therapeutics Inc. filed an 8-K on November 7, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specifi
• Summit Therapeutics Files 8-K on Key Agreements and Sales — Oct 22, 2025 Risk: medium
  On October 21, 2025, Summit Therapeutics Inc. filed an 8-K report detailing several key events. The filing includes information on the entry into a material def
• Summit Therapeutics Files 8-K with Financials — Sep 8, 2025 Risk: low
  Summit Therapeutics Inc. filed an 8-K on September 8, 2025, reporting on events that occurred on September 7, 2025. The filing primarily concerns financial stat
• Summit Therapeutics Files 8-K: Material Agreement & Exhibits — Aug 11, 2025 Risk: medium
  On August 11, 2025, Summit Therapeutics Inc. filed an 8-K report. The filing indicates an entry into a material definitive agreement and includes financial stat
• Summit Therapeutics Inc. Enters Material Definitive Agreement — Jun 20, 2025 Risk: medium
  On June 16, 2025, Summit Therapeutics Inc. entered into a material definitive agreement. The company, headquartered in Miami, FL, filed an 8-K report with the S
• Summit Therapeutics Inc. Files 8-K on Shareholder Vote Matters — Jun 17, 2025 Risk: low
  Summit Therapeutics Inc. filed an 8-K on June 17, 2025, reporting on matters submitted to a vote of security holders as of June 12, 2025. The filing details cor
• Summit Therapeutics Files 8-K — May 30, 2025 Risk: low
  Summit Therapeutics Inc. filed an 8-K on May 30, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific fi
• Summit Therapeutics Files 8-K — Apr 25, 2025 Risk: low
  Summit Therapeutics Inc. filed an 8-K on April 25, 2025, reporting other events and financial statements. The company, formerly known as Summit Therapeutics plc
• Summit Therapeutics Inc. Files 8-K — Apr 23, 2025 Risk: low
  Summit Therapeutics Inc. filed an 8-K on April 23, 2025, reporting other events and financial statements. The company, incorporated in Delaware with its princip
• Summit Therapeutics Files 8-K on Financials — Feb 24, 2025 Risk: low
  On February 24, 2025, Summit Therapeutics Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, a
• Summit Therapeutics Inc. Announces Board and Executive Changes — Jan 24, 2025 Risk: medium
  Summit Therapeutics Inc. announced on January 22, 2025, changes in its board of directors and executive compensation arrangements. The filing details the depart
• Summit Therapeutics Files 8-K on Financials — Jan 13, 2025 Risk: low
  Summit Therapeutics Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation F
• Summit Therapeutics Files 8-K: Material Agreement & Equity Sales — Sep 12, 2024 Risk: medium
  On September 11, 2024, Summit Therapeutics Inc. entered into a material definitive agreement. The company also disclosed unregistered sales of equity securities
• Summit Therapeutics Files 8-K Report — Sep 9, 2024 Risk: low
  On September 8, 2024, Summit Therapeutics Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure, Other Events, and Financial Statemen
• Summit Therapeutics Files 8-K: Material Agreement & Officer Changes — Jun 27, 2024 Risk: medium
  On June 27, 2024, Summit Therapeutics Inc. filed an 8-K report detailing a material definitive agreement and changes in its board and officer composition. The f
• Summit Therapeutics Approves New Equity Incentive Plan — Jun 17, 2024 Risk: medium
  Summit Therapeutics Inc. announced on June 12, 2024, that its Board of Directors has approved a new equity incentive plan. This plan allows for the granting of
• 8-K Filing — Jun 3, 2024
• Summit Therapeutics Files 8-K Report — May 30, 2024 Risk: low
  On May 30, 2024, Summit Therapeutics Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific ma
• Summit Therapeutics Files 8-K — May 24, 2024 Risk: low
  Summit Therapeutics Inc. filed an 8-K on May 24, 2024, reporting other events and financial statements. The company, incorporated in Delaware, has its principal
• Summit Therapeutics Files 8-K: Material Agreement & Exhibits — May 13, 2024 Risk: medium
  On May 13, 2024, Summit Therapeutics Inc. filed an 8-K report. The filing indicates an entry into a material definitive agreement and includes financial stateme
• Summit Therapeutics Inc. Files 8-K: Leadership and Compensation Changes — Apr 11, 2024 Risk: medium
  On April 11, 2024, Summit Therapeutics Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing
• Summit Therapeutics Appoints New CMO and CSO, Adds to Board — Apr 3, 2024 Risk: medium
  Summit Therapeutics Inc. announced on April 2, 2024, the appointment of Dr. Jonathan Edward as Chief Medical Officer and Dr. Kevin J. Lee as Chief Scientific Of
• Summit Therapeutics Files 8-K: Financials & Exhibits — Mar 22, 2024 Risk: low
  On March 22, 2024, Summit Therapeutics Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material even
• Summit Therapeutics Files 8-K — Mar 12, 2024 Risk: low
  On March 12, 2024, Summit Therapeutics Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. No s
• Summit Therapeutics Relocates Principal Executive Offices — Mar 5, 2024 Risk: low
  On March 5, 2024, Summit Therapeutics Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices from Menlo Park, CA t
• Summit Therapeutics Files 8-K for Regulation FD Disclosure on Feb 15, 2024 — Feb 15, 2024 Risk: medium
  Summit Therapeutics Inc. filed an 8-K with the SEC on February 15, 2024, reporting an event that occurred on February 14, 2024. The filing indicates disclosures
• Summit Therapeutics Relocates HQ to Miami, FL — Feb 8, 2024 Risk: low
  Summit Therapeutics Inc. filed an 8-K on February 8, 2024, reporting an 'Other Event' that occurred on February 7, 2024. The filing updates the company's princi
• Summit Therapeutics Relocates HQ to Miami, FL — Jan 8, 2024
  Summit Therapeutics Inc. filed an 8-K on January 8, 2024, to report a change in its principal executive offices from 2882 Sand Hill Road, Suite 106, Menlo Park,
• Summit Therapeutics Updates Business Address & Phone in 8-K Filing — Jan 3, 2024
  Summit Therapeutics Inc. filed an 8-K on January 3, 2024, to update its corporate information, specifically its business address to 2882 Sand Hill Road, Suite 1

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX